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Abstract
Pharmaceutical compounds end up in wastewater treatment plants but little is known on their effect towards the different
microbial groups in anaerobic communities. In this work, the effect of the antibiotic Ciprofloxacin (CIP), the non-steroidal
anti-inflammatory drugs Diclofenac (DCF) and Ibuprofen (IBP), and the hormone 17α-ethinylestradiol (EE2), on the activity
of acetogens and methanogens in anaerobic communities, was investigated. Microbial communities were more affected by
CIP, followed by EE2, DCF and IBP, but the response of the different microbial groups was dissimilar. For concentrations of
0.01 to 0.1 mg/L, the specific methanogenic activity was not affected. Acetogenic bacteria were sensitive to CIP
concentrations above 1 mg/L, while DCF and EE2 toxicity was only detected for concentrations higher than 10 mg/L, and
IBP had no effect in all concentrations tested. Acetoclastic methanogens showed higher sensitivity to the presence of these
micropollutants, being affect by all the tested pharmaceutical compounds although at different degrees. Hydrogenotrophic
methanogens were not affected by any concentration, indicating their lower sensitivity to these compounds when compared
to acetoclasts and acetogens.
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Introduction
The contamination of wastewater with pharmaceuticals is
an environmental problem and a public health concern
(Carpenter et al. 2002; Vasquez et al. 2014). Some phar-
maceuticals cause endocrine disruption (Khetan and Col-
lins 2007; Corcoran et al. 2010) and increase bacterial
resistance to antibiotics (Bouki et al. 2013), leading to
important shifts in microbial communities in the ecosys-
tem (Fountoulakis et al. 2008; Ji et al. 2013). Although
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pharmaceuticals are usually detected in wastewater in
relatively low concentrations (in the range of ng/L to µg/L)
(Jones et al. 2005; Quintana et al. 2005; Liebig et al. 2006;
Radjenovic et al. 2007; Scheurell et al. 2009; Jelic et al.
2011; Gonzalez-Gil et al. 2016; Subedi and Loganathan
2016), higher levels (14 to 31 mg/L of ciprofloxacin (CIP))
have already been detected in the effluents of wastewater
treatment plants (WWTP) in India (Larsson et al. 2007;
Fick et al. 2009) as well as in the surface water from two
lakes in India that were not contaminated by the WWTP,
and in wells of six nearby villages (Fick et al. 2009). In
Portugal, 17.5 µg/L of CIP (Pereira et al. 2015), 2.4 µg/L
of ibuprofen (IBP) (Pereira et al. 2015; Sousa 2015),
8.6 µg/L of diclofenac (DCF) (Pereira et al. 2015; Sousa
2015) and 0.19 µg/L of 17 α-ethinylestradiol (EE2) (Fon-
seca et al. 2013), are usually found in wastewater (WWTP
influents). However, the concentration of pharmaceutical
compounds adsorbed in sewage sludge can be much
higher. For example, sewage sludge from different sites in
USA (US EPA 2009) contained CIP and IBP concentra-
tions in the range of 74.5 to 47500 µg/Kg of dry-weight
sludge, and 99.5 to 11900 µg/Kg of dry-weight sludge,
respectively. In a Spanish WWTP, DCF reached con-
centrations of 200 µg/Kg of dry-weight of primary sludge
(Radjenović et al. 2009), and in Germany, DCF con-
centrations of 7020 µg/Kg total suspended solids in pri-
mary sludge and 310 µg/Kg of total suspended solids in
secondary sludge could be detected (Ternes et al. 2004).
Dissemination of pharmaceuticals in the environment via
contaminated sludge and effluents has been found in soil
(Carter et al. 2014; Li 2014; Malmborg and Magnér 2015),
crops (Wu et al. 2012), surface water (Zhou et al. 2009; Mei
et al. 2018), groundwater and even drinking water (Car-
valho et al. 2013; Cetecioglu et al. 2013). To date, several
sludge and wastewater technologies have been proposed to
solve this problem, and include conventional activated
sludge and membrane bioreactor treatments, sedimentation,
hydrolysis and chlorination (Carvalho et al. 2013; Cete-
cioglu et al. 2013; Jung et al. 2015; Krzeminski et al. 2019).
However, treatment efficiencies are still very low and/or
involve high costs, require high energy input, and may
produce residual toxic by-products (Trapido et al. 2014;
Jung et al. 2015; Silva et al. 2016; Hasan et al. 2016;
Campbell 2017). Therefore, more research is needed to
develop new treatment solutions for sludge and wastewater
contaminated with pharmaceuticals. The treatment by
anaerobic digestion (AD) is a possibility which brings
several advantages such as the recovery of energy from
sludge and wastewater (in the form of biogas), thus con-
tributing to the energy autonomy of WWTP (Eiroa et al.
2012; Mayumi et al. 2016; Chen et al. 2017). However,
prior application of AD to contaminated waste/wastewater it
is important to evaluate the possible effects of
pharmaceuticals on the activity of anaerobic microorgan-
isms. In AD, microbial communities are composed by
several microbial groups with distinct physiological activ-
ities and substrate specificities, that interact with each other.
For instance, the last steps of AD are catalyzed by aceto-
genic bacteria, which convert volatile fatty acids (e.g.,
butyrate, propionate) to acetate, hydrogen and carbon
dioxide, and by acetoclastic and hydrogenotrophic metha-
nogens that utilize the acetate and the hydrogen (plus car-
bon dioxide) for methane production, respectively.
Acetogenesis and methanogenesis are crucial steps in AD,
occurring after hydrolysis and acidogenesis of complex
organic matter (i.e., proteins, carbohydrates or lipids). Thus,
it is desirable that the activity of acetogens and methano-
gens is not compromised by the presence of toxicants in
AD, to guarantee the treatment efficiency.
The literature reports a number of studies where complex
substrates such as casein, glucose or peptone were used to
assess the effect of pharmaceuticals, instead of the direct
substrates for methanogens and acetogens (Fountoulakis
et al. 2004; Campbell 2013; Liu et al. 2013; Zhao et al.
2018).
In this work, the effect of CIP, IBP, DCF and EE2, on
the activity of anaerobic communities, was investigated by
using specific substrates for methanogens (H2/CO2 for
hydrogenotrophic methanogens, and acetate for acetoclastic
methanogens) and acetogens (a mixture of volatile fatty
acids), and by following methane production.
Materials and methods
Preparation of pharmaceutical solutions
CIP (CAS 85721-33-1, purity ≥98%), IBP (CAS 15687-
27-1, purity ≥98%), DCF (CAS 15307-79-6, purity ≥98%)
and EE2 (CAS 57-63-6, purity ≥98%) were purchased
from Sigma-Aldrich. The tested concentrations of each
pharmaceutical ranged between 0.01 mg/L and 100 mg/L.
For the concentrations between 0.01 mg/L and 0.1 mg/L,
stock solutions of 1 mg/L were prepared in deionized
water. For higher concentrations, a stock of 1250 mg/L
was prepared also in deionized water for DCF, while for
the other pharmaceuticals, due to their low solubility in
water, it was necessary to prepare stock solutions
(1250 mg/L) as following: (1) solution of CIP in water
with a few drops of hydrochloric acid (2 M); (2) addition
of methanol to IBP and (3) addition of ethanol to EE2, as
described in Table 1. CIP has a water solubility of 30 g/L
at 20 °C, which is enhanced when it is in the ionic form,
explaining the higher solubility in acidic media. IBP and
EE2, also have low solubility in water, 21 mg/L at 25 °C
and 11.3 mg/L at 27 °C.
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Batch experiments set-up
The effect of pharmaceuticals on AD was assessed by
determining the specific methanogenic activity (SMA) of an
anaerobic granular sludge, collected from the anaerobic
digester treating a brewery wastewater. The assays were
carried out in the presence of increasing concentrations of
CIP, IBP, DCF and EE2 (Table 1). SMA of the anaerobic
sludge was determined as described elsewhere (Alves et al.
2001).
The effect of CIP, IBP, DCF and EE2 on the activity of
hydrogenotrophic methanogens, acetoclastic methanogens
and acetogens was determined by incubating the anaerobic
sludge with the following substrates as carbon and energy
sources: H2/CO2 (80:20% v/v, at 1.7 × 10
5 Pa) for hydro-
genotrophic methanogens; acetate (30 mM) for acetoclastic
methanogens; and a mixture of VFA (10 mM acetate,
10 mM propionate and 5 mM butyrate) for acetogenic bac-
teria. In this later case, the assessed effect is indirect as the
specific activity of acetogens is only directly measured
when hydrogenotrophic and acetoclastic activities are not
rate limiting.
The assays were conducted in closed serum bottles of
25 mL of capacity, for liquid substrates (acetate, and VFA
mixture), and of 70 mL for the gaseous substrate (H2/CO2
(80:20% v/v, at 1.7 × 105 Pa) and N2/CO2 (80:20% v/v, at
1.7 × 105 Pa) used in the blank assay). The working
volume was 12.5 mL in all assays and consisted in anae-
robic medium containing deionized water with resazurin
(1 g/L) and sodium bicarbonate (3 g/L). No reducing agent
was added and the pH was corrected to values between 7.0
and 7.2. Anaerobic biomass was added at a final con-
centration of 3 g/L of volatile solids (VS). The bottles were
sealed with butyl rubber stoppers and aluminum caps, and
the headspace was first flushed with N2/CO2 (80:20% v/v),
and then depressurized to atmospheric pressure. Before
adding the substrates and the pharmaceuticals, the bottles
were incubated overnight (37 °C and 110 rpm), to promote
the consumption of the residual substrate by the biomass,
and for temperature acclimation. After overnight incuba-
tion, the bottles headspace was flushed again with a mix-
ture of N2/CO2 (80:20% v/v) to remove traces of methane,
depressurized, and the substrates were added: 0.125 mL
for liquid substrates (from 100x concentrated stock solu-
tions) and H2/CO2 (80:20% v/v) (1 bar overpressure).
Pharmaceutical compounds were added in concentrations
ranging from 0.01 mg/L and 100 mg/L (Table 1). Initial
methane production rate was assessed by measuring
increasing pressure developed in the liquid substrate
assays followed by analysis by Gas Chromatography
(GC). The analyses were performed in a GC Chrompack
9000, equipped with a Propack Q, 80/100 mesh column,
with N2/Air and Argon as carrier gases, at a flow of 30 and
5 mL/min, respectively. Injector, column and detector
temperatures were 110, 35 and 220 °C, respectively. For
H2/CO2 consumption, the decrease in pressure was
assessed and the rate of methane production was obtained,
by stoichiometric calculations (pressure decreases because
4 moles of H2/CO2 are needed to produce 1 mol of
methane) (Supplementary Information Figure 1). Blank
assays (B) were prepared without pharmaceuticals, and
without substrate. Control assays (SC) were performed
without pharmaceuticals but with the specific substrate, to
determine the SMA without pharmaceuticals. All the
assays were performed in triplicate.
IBP and EE2 stock solutions were prepared with organic
solvents, and therefore additional controls were prepared
(OSS – Control with organic solvent and specific substrate;
OS – Control with organic solvent), in duplicate, in order to
distinguish the effect of the pharmaceutical from the effect
of the organic solvent (methanol and ethanol), as potential
inhibitors or additional substrates (Table 1). In addition, due
to the insolubility of IBP and EE2 at concentrations equal to
or exceeding 100 mg/L, assays with this concentration were
performed by adding all the pharmaceutical compounds in
powder directly in the incubation bottles.
Table 1 Experimental
conditions for the determination




Pharmaceutical Pharmaceutical (mg/L) Solvent Controls
CIP 0.01; 0.1 Water B; SC
1; 5; 10; 50 and 100 Water with HCla
DCF 0.01; 0.1; 1; 5; 10; 50 and 100 Water B; SC
IBP 0.01; 0.1 Water B; SC
1; 5; 10; 50 Methanol/Water 37% (v/v) B; SC; OSS and OS
EE2 0.01; 0.1 Water B; SC
1; 5; 10; 50 Ethanol/Water 47% (v/v) B; SC; OSS and OS
a250 µL of HCl (2M) were added to 100 mL of the stock solution prepared in deionized water
Blank (B) – Without substrate, pharmaceutical or solvent; Substrate control (SC) – Only substrate added to
the buffer (no pharmaceutical and no solvent); Organic solvent controls – No pharmaceutical addition to the
buffer, only the organic solvent in the concentrations correspondent to that of the tests with pharmaceuticals,
either with substrate (OSS) or without substrate (OS)
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Statistical analysis
Statistical analysis was performed using the GraphPad
software, to verify if there were significant differences
between the effects associated with the addition of phar-
maceutical, as powder or as solution, at the maximum
concentrations tested. F test was used to verify the homo-
geneity of variances, followed by the parametric unpaired
t test with a p-value of 0.05, which was used to verify if the
differences were significant.
Results and discussion
The anaerobic sludge used in this study showed metha-
nogenic activity with all the substrates tested, as methane
was produced in control assays (without pharmaceuticals).
The highest SMA was obtained in H2/CO2 (515 ± 52
mLCH4@SPT/gVS.day) assays, and in acetate and VFA,
the SMA was 79 ± 11 mLCH4@SPT/gVS.day and 82 ± 13
mLCH4@SPT/gVS.day, respectively. In the assays per-
formed with pharmaceuticals, no inhibition associated
with the presence of pharmaceuticals was observed at the
minimal concentration assessed (0.01 mg/L) (Table 2),
which is the closest concentration to the ones found in real
WWTP (Fonseca et al. 2013; Pereira et al. 2015; Sousa
2015). The SMA was also not affected by any of the
tested pharmaceuticals at concentrations up to 0.1 mg/L
(Table 2), which is higher than the concentrations found
in WWTP (Fonseca et al. 2013; Pereira et al. 2015; Sousa
2015). It should be highlighted that hydrogenotrophic
activity was not inhibited by any of the pharmaceuticals,
regardless of concentration (Table 2). Overall, the anae-
robic communities were most affected by the presence of
CIP, followed by EE2 and DCF, and less by IBP, when
present at concentrations higher than 0.1 mg/L. In the case
of IBP or EE2, to assess the inhibitory effect, it was
necessary to subtract the effect of the organic solvents and
ethanol on the SMA, as they can serve as additional
energy and carbon sources or function as microbial inhi-
bitors (Supplementary Information Table 1). For instance,
although the percentages of inhibition in the assays of
EE2 with H2/CO2 were around 36%, these were close to
the inhibition obtained in the respective solvent control,
OSS (around 38%) (Table 2 and Supplementary Infor-
mation Table 1), leading to the conclusion that EE2 did
not affect the hydrogenotrophic activity. This conclusion
is corroborated by the assay in which EE2 was added in
powder at 100 mg/L, where no inhibition was detected
(Table 2).
The highest SMA inhibition percentages were obtained
for the acetoclastic activity, showing that acetoclastic
methanogens were the most affected (Table 2). However,
for CIP, at concentrations up to 10 mg/L of CIP, acetogenic
bacteria were the most sensitive to the presence of the
antibiotic: ≈30% of inhibition. with 1–100 mg/L of CIP. On
the other hand, at CIP concentrations higher than 10 mg/L,
acetoclastic activity was the most affected with circa 45% of
inhibition (Table 2).
The same concentration of CIP added in solution or in
powder resulted in different inhibitory percentages, with
CIP in powder exerting the highest inhibition towards
acetoclastic methanogens (76 ± 4% with CIP in powder,
compared to 43 ± 2% with CIP in solution) (Table 2, Sup-
plementary Information Table 2 and Supplementary Infor-
mation Figure 1). This difference may be related to the
adsorption of CIP on the anaerobic sludge (Genç et al.
2013; Zhang et al. 2018).
Table 2 Percentage of SMA
inhibition in the presence of
different substrates at increasing
concentrations of CIP, DCF, IBP
and EE2
Substrate Pharmaceutical (mg/L) Inhibition (%)
[0.01 – 0.1] 1 5 10 50 100 (S) 100 (P)
Acetate CIP 0 18 ± 3 16 ± 7 14 ± 7 45 ± 8 43 ± 2 76 ± 4
VFA 0 27 ± 9 25 ± 5 29 ± 9 28 ± 5 32 ± 2 21 ± 6
H2/CO2 0 0 0 0 0 0 0
Acetate DCF 0 0 0 0 18 ± 5 39 ± 4 38 ± 8
VFA 0 0 0 16 ± 5 15 ± 6 28 ± 7 0
H2/CO2 0 0 0 0 0 0 0
Acetate IBP 0 0 0 0 14 ± 7 n.a 20 ± 6
VFA 0 0 0 0 0 n.a. 0
H2/CO2 0 0 0 0 0 n.a. 0
Acetate EE2 0 0 0 6 ± 3 24 ± 5 n.a. 51 ± 3
VFA 0 0 0 17 ± 4 20 ± 1 n.a. 23 ± 2
H2/CO2 0 0 0 0 0 n.a. 0
n.a. not applicable
S solution, P powder
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Given the lower solubility of CIP, it is possible that it
was adsorbed onto the sludge when added as a powder to
the medium at neutral pH, increasing the contact between
CIP and microbial cells and, consequently, the inhibitory
effect. On the other hand, in the assay with VFA as sub-
strate, the results obtained with CIP in solution (32 ± 2%)
and in powder (21 ± 6%) were similar (p value of 0.0964))
(Table 2 and Supplementary Information Table 2). These
results were close to the obtained by Liu et al. (2013), who
reported a methanogenic inhibition of 36% with 100 mg/L
of CIP. In that study the sludge was a methanogenic cul-
ture collected from a municipal anaerobic digester, which
was fed with a mixture of dextrin and peptone (Table 3).
Other studies showed higher sensitivity of anaerobic
sludge to CIP for concentrations higher than 0.05 mg/L:
50% of inhibition at a concentration of CIP of 4.8 mg/L,
with a mixture of glucose, peptone and meat extract (Mai
et al. 2018), and 43 and 69% at concentrations of 0.3 mg/L
and 15 mg/L of CIP, respectively, with a mixture of
nutrient broth, yeast extract and glucose (Zhao et al. 2018)
(Table 3). The differences in the results presented in the
literature may be justified by the use of different complex
substrates, assessing the overall activity of the anaerobic
community, instead of the activity of specific groups. In
our study, only the acetoclastic and acetogenic commu-
nities were sensitive to CIP at concentrations higher or
equal to 1.0 g/L, which is in good agreement with the
study of Mai et al. (Mai et al. 2018), who observed a
decrease in the relative abundance of these communities,
in the presence of this antibiotic.
DCF only inhibited the acetogenic activity at con-
centrations ≥10 mg/L, and the acetoclastic activity at
concentrations ≥50 mg/L, doubling the inhibition percen-
tage when the DCF concentration increased from 50 to
100 mg/L (Table 2). When DCF was added as powder
(100 mg/L), the inhibition of the acetoclastic activity was
similar (p value of 0.8844) to the obtained with the
solution of 100 mg/L of DCF (around 40%) (Table 2 and
Supplementary Information Table 2). However, no effect
was observed towards the acetogenic plus methanogenic
community when DCF was added as powder (Table 2),
although 100 mg/L of DCF in solution caused an inhibi-
tion of 28 ± 7%. The differences between the inhibitory
results obtained with DCF in powder and in solution may
be related to the low DCF adsorption capability on the
anaerobic sludge (Samaras et al. 2013). In solution, at pH
7, DCF is negatively charged due to its pKa= 4.15
(Zhang et al. 2008). As anaerobic sludge is also negatively
charged (Jia et al. 1996; Alvarino et al. 2018), the
adsorption between the DCF and the biomass will be
reduced, due to growing repulsion electrostatic interac-
tions and a reduction in π–π interactions. Moreover, when
DCF is added as powder, despite being solubilised in the
medium, it will not be immediately available for the
microorganisms as when added as solution, which may
result in lower toxicity. These results are in good agree-
ment with Fountoulakis et al. (Fountoulakis et al. 2004),
who described 50% of inhibition of the acetoclastic
methanogens with 120 mg/L of DCF and a mixture of
acetate, casein and yeast extract (Table 3). However,
inhibition of acetoclastic methanogenesis of 46% was
obtained by Hu et al. (Hu et al. 2018), for 0.667 mg/L of
DCF, with activated sludge from a secondary sedimenta-
tion tank of a municipal WWTP as inoculum, and acetate
as substrate, revealing a higher susceptibility of that cul-
ture to DCF. A lower effect caused by DCF was obtained
by Symsaris et al. (Symsaris et al. 2015), using acetate
(Table 3).
The low sensitivity of hydrogenotrophic methanogens to
DCF, compared to other microbial groups is also supported
by other works (Table 3) (Symsaris et al. 2015; Hu et al.
2018).
Regarding IBP and EE2, the results obtained for the
highest concentrations correspond to the effect of the
pharmaceutical compound in solution discounting the effect
of the correspondent inhibition caused by the OSS on the
SMA (Supplementary Information Table 1). IBP did not
cause inhibition to any group, except for the acetoclastic
mehanogens (20% with 100 mg/L) (Table 2).
To date, the reports reveal no inhibitory effect of IBP at
concentrations up to 206 mg/L (Campbell 2013, 2017) but
the results were obtained with an anaerobic inoculum that
was previously adapted to it (Campbell 2017), or using
complex substrates (Campbell 2013), reflecting the overall
activity of the anaerobic community, instead of the activity
of specific groups involved in the methanogenic process
(Table 3).
Concerning EE2, the inhibitory effect towards the
acetoclastic methanogens was considered negligible for
10 mg/L, while for 50 mg/L, the acetoclastic activity was
inhibited 24 ± 5%. Regarding the assay with VFA, inhibi-
tion of circa 20%, was obtained for concentration equal and
above 10 mg/L (Table 2). Any effect was observed on
acetogenic activity, for concentrations up to 5 mg/L, neither
for acetoclastic at concentration up to 10 mg/L (Table 3).
EE2 did not cause inhibition of the hydrogenotrophic
community at any of the concentrations tested. To date, the
reports available reveal no inhibitory effect of EE2 at con-
centrations up to 2 mg/L (Hom-Diaz et al. 2016).
Conclusion
In this work, the effect of pharmaceuticals ciprofloxacin
(CIP), ibuprofen (IBP), diclofenac (DCF) and 17α-ethi-
nylestradiol (EE2) on anaerobic communities was
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evaluated. None of these pharmaceuticals affected the
specific methanogenic activity at concentrations up to
0.1 mg/L, which are closer to the ones found in the
influents of WWTP. For higher concentrations (1 to
100 mg/L), acetoclastic methanogens were the most
affected, and were inhibited in ≈20% by 1 mg/L of CIP,
and in circa 50% with higher antibiotic concentrations.
The activity of acetogens together with methanogens was
affected by all pharmaceuticals, except by IBP, while
hydrogenotrophic methanogens were not affected by any
pharmaceutical. Taking all the results in consideration, it
can be concluded that the anaerobic communities were
not severely affected by these compounds and therefore,
the application of the anaerobic digestion for the treat-
ment of wastewater, and for the digestion of sewage
sludge contaminated with pharmaceuticals seems fea-
sible. As future work, the effect of pharmaceuticals by
using a real contaminated wastewater and real con-
taminated activated sludge should be assessed to deter-
mine the efficiency of the anaerobic digestion treatment
with such contaminants.
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